机构：[1]Department of Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China,内科科室肿瘤内科昆明医科大学附属第一医院[2]Department of Oncology, The People’s Hospital of Puer City, Puer, China,[3]Department of Gastroenterology, The 920th Hospital of the Joint Logistics Support Force, PLA, Kunming, China,[4]Department of Prevention and Health Care, The First Affiliated Hospital of Kunming Medical University, Kunming, China,昆明医科大学附属第一医院[5]The Medical Department, 3D Medicines Inc., Shanghai, China
Gastric cancer is one of the most common cancers, while the current treatment options for gastric cancer are relatively scarce due to insufficient understanding of molecular characteristics and subtypes of gastric cancer. Different gene rearrangements of anaplastic lymphocyte kinase (ALK) have been reported in several types of cancer, especially in NSCLC. The first-generation ALK tyrosine kinase inhibitor (TKI) crizotinib, second-generation (ceritinib, alectinib, and brigatinib) and third-generation (lorlatinib) ALK-TKIs have been widely used for NSCLC patients with ALK rearrangement. However, little was reported about ALK mutation in gastric cancer (GC). Here we identified a novel form of ALK fusion, a case of GC with RAB10-ALK fusion, and this is the first report of ALK fusion in gastric cancer.
第一作者机构：[1]Department of Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China,
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhengqi Wen,Dun Xiong,Shurong Zhang,et al.Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.645370.
APA：
Zhengqi Wen,Dun Xiong,Shurong Zhang,Jiankun Liu,Bitao Li...&Hushan Zhang.(2021).Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer.FRONTIERS IN ONCOLOGY,11,
MLA：
Zhengqi Wen,et al."Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer".FRONTIERS IN ONCOLOGY 11.(2021)
